Systemic and Intracranial Efficacy and Safety of Trastuzumab Deruxtecan in HER2-Mutant NSCLC Acr

24 Feb 20265 min read0 viewsJournal Feed

GIST (Key Takeaways)

HER2 mutations define a distinct, therapeutically actionable subset of non-small cell lung cancer (NSCLC).
Trastuzumab deruxtecan (T-DXd) has demonstrated strong activity in clinical trials, but real-world data are limited.

Clinical Editorial

Journal of Thoracic Oncology (JTO) published a clinical update in Oncology on 24 Feb 2026.

The item focuses on Systemic and Intracranial Efficacy and Safety of Trastuzumab Deruxtecan in Patients with HER2-Mutant Non-Small Cell Lung Cancer across Treatment Lines: Evidence from the TRACER/HERTras Real-World Cohort.

Review the original article for the full source wording and details.